A Study of the Safety and Clinical Effects of Interferon Gamma-1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
Study GIPF-002 is a phase 2 study designed to characterize the biologic and clinical effects
of IFN-g 1b. The objective of the Study is to characterize the biologic and clinical effects
of IFN-g 1b administered to patients with idiopathic pulmonary fibrosis (IPF). The Study will
be conducted at multiple sites and enroll 30 patients with IPF who have failed treatment with
corticosteroids.